MARKET

ATRS

Antares Pharma Inc
ATRS
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
14.76
5.31
5.41
955,065,066.93
Looking Into Antares Pharma's Return On Invested Capital
Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter.
Benzinga · 06/08 13:55
5 Reasons Why You Should Add Halozyme (HALO) to Your Portfolio
We provide five reasons, which make Halozyme (HALO) a good investment option in 2022.
Zacks · 05/19 13:35
Halozyme Says Antitrust Act Waiting Period Expires for Antares Pharma Acquisition
MT Newswires · 05/12 09:58
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
On Assertio Holdings' (ASRT) Q1 earnings call, investors will focus on the sales performance of its marketed products.
Zacks · 04/26 17:20
Halozyme Reports Tender Offer To Buy All Shares Of Antares Pharma At $5.60/Share In Cash
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme") today announced that it is commencing, through a wholly owned subsidiary, Atlas Merger Sub, Inc. ("Purchaser"), a cash tender offer to
Benzinga · 04/26 12:15
Halozyme Therapeutics Launches Cash Tender Offer to Acquire Antares Pharma Shares
MT Newswires · 04/26 10:29
Analysts Are Downgrading These 10 Pharmaceutical Stocks
In this article, we present the 10 pharmaceutical stocks that are being downgraded by analysts. You can skip our analysis of the pharmaceutical industry and go directly to Analysts Are Downgrading These 5 Pharmaceutical Stocks. The pharmaceutical industry ...
Insider Monkey · 04/20 13:17
Antares Pharma downgraded by Raymond James, 4 others after Halozyme ~$1B acquisition offer
Antares Pharma (NASDAQ:ATRS) was downgraded by five firms — Truist, Ladenburg, Raymond James, Piper Sandler and H.C. Wainwright — after Halozyme Therapeutics (HALO) said on April 13 that it was acquiring
Seekingalpha · 04/14 14:58
More
No Data
Learn about the latest financial forecast of ATRS. Analyze the recent business situations of Antares Pharma Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
16.67%Buy
83.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATRS stock price target is 5.95 with a high estimate of 7.00 and a low estimate of 5.60.
High7.00
Average5.95
Low5.60
Current 5.59
EPS
Actual
Estimate
0.040.090.140.19
Q2 2021
Q3 2021
Q4 2021
  • 0
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 229
Institutional Holdings: 97.11M
% Owned: 56.84%
Shares Outstanding: 170.85M
TypeInstitutionsShares
Increased
59
9.68M
New
18
1.40M
Decreased
55
5.18M
Sold Out
22
2.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.19%
Healthcare Equipment & Supplies
+0.50%
Key Executives
Non-Executive Chairman/Independent Director
Leonard Jacob
President/Chief Executive Officer/Director
Robert Apple
Chief Financial Officer/Executive Vice President
Fred Powell
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Peter Graham
Executive Vice President
Peter Richardson
Director
Carmen Volkart
Independent Director
Thomas Garrity
Independent Director
Peter Greenleaf
Independent Director
Anton Gueth
Independent Director
Robert Roche
Independent Director
Karen Smith
No Data
No Data

Webull offers kinds of Antares Pharma Inc stock information, including NASDAQ:ATRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATRS stock methods without spending real money on the virtual paper trading platform.